Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short Interest

Aligos Therapeutics, Inc. (NASDAQ:ALGS) saw a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 291,500 shares, a growth of 140.3% from the October 31st total of 121,300 shares. Approximately 11.5% of the shares of the company are short sold. Based on an average trading volume of 266,300 shares, the short-interest ratio is presently 1.1 days.

Aligos Therapeutics Stock Performance

Shares of ALGS opened at $22.99 on Thursday. Aligos Therapeutics has a 52 week low of $6.76 and a 52 week high of $30.00. The firm has a market capitalization of $82.53 million, a P/E ratio of -1.73 and a beta of 2.11. The company has a 50-day simple moving average of $11.25 and a 200-day simple moving average of $12.54.

Aligos Therapeutics (NASDAQ:ALGS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($3.07) EPS for the quarter, missing analysts’ consensus estimates of ($2.15) by ($0.92). The firm had revenue of $1.27 million during the quarter, compared to the consensus estimate of $1.00 million. Aligos Therapeutics had a negative return on equity of 114.34% and a negative net margin of 1,283.19%. During the same quarter in the prior year, the business posted ($10.25) EPS. As a group, equities analysts forecast that Aligos Therapeutics will post -10.36 earnings per share for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Opaleye Management Inc. raised its position in Aligos Therapeutics by 25.7% in the first quarter. Opaleye Management Inc. now owns 1,630,000 shares of the company’s stock worth $1,597,000 after purchasing an additional 333,000 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of Aligos Therapeutics by 26.1% in the 2nd quarter. Acadian Asset Management LLC now owns 829,485 shares of the company’s stock valued at $289,000 after purchasing an additional 171,490 shares during the period. Finally, Armistice Capital LLC raised its holdings in shares of Aligos Therapeutics by 5.3% in the 2nd quarter. Armistice Capital LLC now owns 7,256,410 shares of the company’s stock worth $2,540,000 after buying an additional 363,000 shares in the last quarter. 60.43% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $75.00 price objective on shares of Aligos Therapeutics in a research report on Thursday, November 7th.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).